NorthWest Biotherapeutics Inc (NWBO)

[AVII77]

after their PACT trial was stopped for futility (I remember that black Monday well).

Censoring and "missing Data" played a central role in my failure to correctly assess the risk in that trial and caused me to misinterpret the delay in the interim being triggered as positive. There too "everyone was living longer".

Senti reposting my comments from that fateful day reminded me of a quote from a favorite book:

“We choose our next world through what we learn in this one. Learn nothing, and the next world is the same as this one, all the same limitations and lead weights to overcome.”

In that spirit, folks here should know about how missing data will be handled in the DCVax Phase 3 trial.

The following types of patients will not count as a progression event in this trial:

A Treatment discontinuation for undocumented progression,
B Treatment discontinuation for toxicity or other reason,
C New anticancer treatment started prior to documented progression,
D Progression after more than one missed visit,
E Death after more than two missed visits.

Understanding the way missing data is handled in a clinical trial is important.